Showing posts with label Biotech. Show all posts
Showing posts with label Biotech. Show all posts
Tuesday, January 21, 2014

Funds-on-Tap is passé & Drip-Funding is the new reality.

›
It’s probably been true for IT/ ITES ( particularly for e-commerce and social media & app-developers ) much longer, but for the drug...
Tuesday, October 15, 2013

Deal-Flow : Value-addition :: Silicon-rapids : Organic back-waters

›
Reacting to the rather weird scenario wherein some VCs are trashing their own brotherhood, Bruce Booth wonders in his latest article if t...
1 comment:
Friday, June 28, 2013

A start-up messed up at its foundation OUGHT TO be fixed!

›
The celebrated venture investment guru Peter Thiel postulated a law that says "a start-up messed up at its foundation cannot be fixed...
Tuesday, March 5, 2013

What could VCs learn from the recent pharma deals involving biotechs with very early-assets?

›
My response on the blog post " Preclinical Biotech Structured Deals: Reflections on 2013′s Solid Start"   by Bruce Booth - post...
Saturday, March 2, 2013

What when the boundaries blur between VC & PE?

›
My response on the highly thought provoking blog post "Venture Capital 2.0"  by Drug Baron (David Grainger) - posted on 01/Mar/2...
1 comment:
Monday, January 28, 2013

Drug discovery unable to attract big money! - Is innovation, rather the lack of it to blame?

›
Some interesting observations on early-stage funding for healthcare from the 2012 Venture Capital Activity Report published by  CB Insight...
Thursday, January 24, 2013

The clinical attrition of INX-189 post a 2.5 billion acquisition - are investors into life sciences really looking at where the buck is headed?

›
October 2012 Discussion initiated on Global Private Equity & Venture Capital  group on Linkedin http://www.linkedin.com/groupItem?vi...
1 comment: